Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus GP regimen in metastatic TNBC
NCT04750382Phase 2Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in triple-negative breast cancer (TNBC), sponsored by Taizhou Hanzhong Pharmaceuticals. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04750382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750382.